EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation

Lingyu Kong iD, Fumei Zhong iD, Fazhi Yu iD, Ting Wang iD, Gang Wang, Yu Bai, Han Xia, Zihang Pan, Mingxue Liu, Yan Zhang, Rui Feng, Jiahai Zhang und 5 weitere

Proceedings of the National Academy of Sciences · 28.04.2026 · 123 (17)

DOI: 10.1073/pnas.2516469123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 20.04.2026. Verfasst von Lingyu Kong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive disease, The First Affiliated Hospital of University of Science and Technology of China (USTC), State Key Laboratory of Immun…. Hauptthemen laut MEDLINE: Aurora Kinase A, Sorafenib, Drug Resistance, Neoplasm, Stress Granules. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mitotic kinase Aurora-A is frequently overexpressed in cancers and contributes to tumor progression and therapy resistance, yet the mechanisms underlying its role in drug resistance remain unclear. Here, we show that sorafenib treatment triggers Aurora-A phase separation, leading to its recruitment into stress granules (SGs), membraneless organelles that promote cancer cell survival. Aurora-A facilitates robust SGs assembly, thereby conferring sorafenib resistance. Mechanistically, upon sorafenib-induced SGs formation, Aurora-A binds RNA via positively charged lysine/arginine residues within its intrinsically disordered region (IDR). Mutating these K/R residues with IDR of Aurora-A disrupts its RNA binding, impairs SGs assembly, and resensitizes cancer cells to sorafenib. Together, our work identifies Aurora-A as a kinase-activity-independent, RNA-binding scaffold essential for stress-adaptive biomolecular condensation, revealing a druggable phase-separation axis distinct from canonical Aurora-A kinase signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aurora Kinase ASorafenibDrug Resistance, NeoplasmStress GranulesPhase SeparationHumansCell Line, TumorAntineoplastic Agents

Stichwörter der Autor:innen

Aurora-Aphase separationsorafenibstress granuletumor therapy

Substanzen

Aurora Kinase ASorafenibAntineoplastic AgentsAURKA protein, human

Autor:innen und Institutionen

  • Department of Digestive disease, The First Affiliated Hospital of University of Science and Technology of China (USTC), State Key Laboratory of Immune Response and Immunotherapy, Division of Life Sciences and Medicine,…
  • Ministry of Education (MOE) Key Laboratory for Cellular Dynamics and Membraneless Organelle, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
  • Chinese Academy of Sciences Key Laboratory of Regenerative Biology, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou Medical University, Guangzhou 511…
  • Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
  • Center for Advanced Interdisciplinary Science and Biomedicine, Institute of Health and Medical Technology, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China.
  • Anhui Key Laboratory of Molecular Oncology, Division of Life Sciences and Medicine, Institute of Cancer Research, University of Science and Technology of China, Hefei 230026, China.

ORCID-Profile: Lingyu Kong, Fumei Zhong, Fazhi Yu, Ting Wang, Jing Guo, Ke Ruan, Zhenye Yang

Förderung

  • MOST | National Key Research and Development Program of China (NKPs)
  • MOST | National Natural Science Foundation of China (NSFC)

Zitieren

APA

Kong, L., Zhong, F., Yu, F., Wang, T., Wang, G., Bai, Y., Xia, H., Pan, Z., Liu, M., Zhang, Y., Feng, R., Zhang, J., Du, Y., Zhang, K., Guo, J., Ruan, K., & Yang, Z. (2026). Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation. Proceedings of the National Academy of Sciences, 123(17). https://doi.org/10.1073/pnas.2516469123

Vancouver

Kong L, Zhong F, Yu F, Wang T, Wang G, Bai Y, et al. Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation. Proceedings of the National Academy of Sciences. 2026;123(17). doi:10.1073/pnas.2516469123

BibTeX
@article{Kong2026,
  author = {Kong, Lingyu and Zhong, Fumei and Yu, Fazhi and Wang, Ting and Wang, Gang and Bai, Yu and Xia, Han and Pan, Zihang and Liu, Mingxue and Zhang, Yan and Feng, Rui and Zhang, Jiahai and Du, Yingying and Zhang, Kaiguang and Guo, Jing and Ruan, Ke and Yang, Zhenye},
  title = {Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {17},
  doi = {10.1073/pnas.2516469123}
}
Kostenlos starten →